Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||BI-1347 + Trametinib|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|BI-1347||BI1347|BI 1347||CDK8 Inhibitor 5||BI-1347 inhibits CDK8 and CDK19, which leads to reduced levels of phosphorylated Stat1 and increased activity of NK cells, potentially resulting in tumor growth inhibition, in combination with other agents (PMID: 32024684, PMID: 36398965).|
|Trametinib||Mekinist||GSK1120212||MEK inhibitor (Pan) 23 MEK1 Inhibitor 25 MEK2 Inhibitor 23||Mekinist (trametinib) inhibits MEK 1 and 2, which potentially leads to reduced tumor cell proliferation (PMID: 27956260). Mekinist (trametinib) is FDA approved for melanoma patients harboring BRAF V600E or BRAF V600K mutations, and in combination with Tafinlar (dabrafenib) for BRAF V600E/K-mutant melanoma, BRAF V600E- mutant non-small cell lung cancer, BRAF V600E-mutant anaplastic thyroid cancer, for adult and pediatric patients of 6 years or older with unresectable or metastatic solid tumors harboring BRAF V600E, and for pediatric patients of 1 year or older with low-grade glioma harboring BRAF V600E (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|NRAS Q61K||neuroblastoma||sensitive||BI-1347 + Trametinib||Preclinical - Cell culture||Actionable||In a preclinical study, the addition of BI-1347 to Mekinist (trametinib) resulted in enhanced growth inhibition of a neuroblastoma cell line harboring NRAS Q61K compared to Mekinist (trametinib) alone in culture (PMID: 36398965).||36398965|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|